Betta Pharmaceuticals Co., Ltd. (SHE:300558)
China
· Delayed Price · Currency is CNY 48.17
-1.35 (-2.73%)
Apr 29, 2026, 3:04 PM CST
Betta Pharmaceuticals Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Market Capitalization | 20,835 | 19,644 | 22,569 | 21,573 | 20,525 | 33,154 | Upgrade
|
| Market Cap Growth | -2.82% | -12.96% | 4.62% | 5.11% | -38.09% | -25.26% | Upgrade
|
| Enterprise Value | 22,953 | 21,688 | 24,170 | 23,045 | 20,899 | 31,905 | Upgrade
|
| Last Close Price | 49.52 | 46.69 | 53.76 | 51.15 | 48.82 | 78.66 | Upgrade
|
| PE Ratio | 47.07 | 64.34 | 56.06 | 61.99 | 141.14 | 86.55 | Upgrade
|
| Forward PE | 26.48 | 26.59 | 29.63 | 42.25 | 65.91 | 49.20 | Upgrade
|
| PS Ratio | 5.58 | 5.44 | 7.80 | 8.78 | 8.64 | 14.76 | Upgrade
|
| PB Ratio | 3.04 | 2.95 | 3.98 | 4.03 | 4.14 | 7.08 | Upgrade
|
| P/TBV Ratio | 5.74 | 5.49 | 9.47 | 7.45 | 6.38 | 11.18 | Upgrade
|
| P/FCF Ratio | 205.13 | 66.69 | 270.04 | - | - | - | Upgrade
|
| P/OCF Ratio | 23.75 | 21.56 | 24.77 | 23.60 | 66.91 | 62.96 | Upgrade
|
| PEG Ratio | - | 3.08 | 3.08 | 3.08 | 3.08 | 3.08 | Upgrade
|
| EV/Sales Ratio | 6.15 | 6.01 | 8.36 | 9.38 | 8.79 | 14.21 | Upgrade
|
| EV/EBITDA Ratio | 18.99 | 19.93 | 28.60 | 39.86 | 46.08 | 61.61 | Upgrade
|
| EV/EBIT Ratio | 37.43 | 40.13 | 50.68 | 82.34 | 100.98 | 91.48 | Upgrade
|
| EV/FCF Ratio | 225.99 | 73.62 | 289.20 | - | - | - | Upgrade
|
| Debt / Equity Ratio | 0.37 | 0.37 | 0.42 | 0.45 | 0.21 | 0.00 | Upgrade
|
| Debt / EBITDA Ratio | 2.12 | 2.26 | 2.82 | 4.17 | 2.27 | 0.02 | Upgrade
|
| Debt / FCF Ratio | 25.22 | 8.36 | 28.67 | - | - | - | Upgrade
|
| Net Debt / Equity Ratio | 0.30 | 0.30 | 0.32 | 0.31 | 0.06 | -0.21 | Upgrade
|
| Net Debt / EBITDA Ratio | 1.70 | 1.81 | 2.13 | 2.90 | 0.70 | -1.90 | Upgrade
|
| Net Debt / FCF Ratio | 20.19 | 6.68 | 21.51 | -9.23 | -0.45 | 4.24 | Upgrade
|
| Asset Turnover | 0.38 | 0.36 | 0.31 | 0.29 | 0.34 | 0.39 | Upgrade
|
| Inventory Turnover | 2.40 | 2.20 | 1.74 | 1.16 | 0.81 | 0.72 | Upgrade
|
| Quick Ratio | 0.62 | 0.48 | 0.38 | 0.58 | 0.59 | 1.36 | Upgrade
|
| Current Ratio | 0.99 | 0.82 | 0.66 | 0.85 | 0.82 | 1.86 | Upgrade
|
| Return on Equity (ROE) | 6.75% | 4.64% | 7.03% | 6.47% | 2.59% | 8.60% | Upgrade
|
| Return on Assets (ROA) | 3.87% | 3.39% | 3.23% | 2.05% | 1.82% | 3.79% | Upgrade
|
| Return on Invested Capital (ROIC) | 5.14% | 4.64% | 6.46% | 4.55% | 4.61% | 10.75% | Upgrade
|
| Return on Capital Employed (ROCE) | 6.80% | 6.20% | 6.40% | 3.80% | 3.60% | 6.50% | Upgrade
|
| Earnings Yield | 2.12% | 1.55% | 1.78% | 1.61% | 0.71% | 1.16% | Upgrade
|
| FCF Yield | 0.49% | 1.50% | 0.37% | -0.84% | -3.43% | -0.70% | Upgrade
|
| Dividend Yield | 0.30% | 0.32% | 0.37% | 0.33% | 0.14% | 0.32% | Upgrade
|
| Payout Ratio | 18.91% | 49.38% | 37.48% | 31.69% | 95.94% | 35.93% | Upgrade
|
| Buyback Yield / Dilution | -0.57% | 0.26% | -0.01% | -0.72% | 0.02% | -2.32% | Upgrade
|
| Total Shareholder Return | -0.27% | 0.58% | 0.37% | -0.39% | 0.16% | -2.00% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.